A comprehensive clinically informed map of dependencies in cancer cells and framework for target prioritization

Clare Pacini(Wellcome Sanger Institute), Emma L. Duncan(Wellcome Sanger Institute), Emanuel Gonçalves(Instituto de Engenharia de Sistemas e Computadores Investigação e Desenvolvimento), James Gilbert(Wellcome Sanger Institute), Shriram G. Bhosle(Wellcome Sanger Institute), Stuart Horswell(Wellcome Sanger Institute), Emre Karakoç(Wellcome Sanger Institute), Howard Lightfoot(Wellcome Sanger Institute), Edward Curry(Age UK), Francesc Muyas(European Bioinformatics Institute), Monsif Bouaboula(Sanofi (United States)), Chandra Sekhar Pedamallu(Sanofi (United States)), Isidro Cortés‐Ciriano(European Bioinformatics Institute), Fiona M. Behan(Age UK), Lykourgos‐Panagiotis Zalmas(Wellcome Sanger Institute), Andrew Barthorpe(Wellcome Sanger Institute), Hayley E. Francies(Age UK), Steve Rowley(Sanofi (United States)), Jack Pollard(Sanofi (United States)), Pedro Beltrão(European Bioinformatics Institute), Leopold Parts(Wellcome Sanger Institute), Francesco Iorio(Wellcome Sanger Institute), Mathew J. Garnett(Wellcome Sanger Institute)
Cancer Cell
January 11, 2024
Cited by 87Open Access
Full Text

Abstract

Genetic screens in cancer cell lines inform gene function and drug discovery. More comprehensive screen datasets with multi-omics data are needed to enhance opportunities to functionally map genetic vulnerabilities. Here, we construct a second-generation map of cancer dependencies by annotating 930 cancer cell lines with multi-omic data and analyze relationships between molecular markers and cancer dependencies derived from CRISPR-Cas9 screens. We identify dependency-associated gene expression markers beyond driver genes, and observe many gene addiction relationships driven by gain of function rather than synthetic lethal effects. By combining clinically informed dependency-marker associations with protein-protein interaction networks, we identify 370 anti-cancer priority targets for 27 cancer types, many of which have network-based evidence of a functional link with a marker in a cancer type. Mapping these targets to sequenced tumor cohorts identifies tractable targets in different cancer types. This target prioritization map enhances understanding of gene dependencies and identifies candidate anti-cancer targets for drug development.


Related Papers